Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CA3 | P07451 | 3/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 1.00 |
| ▸ | CA6 | P23280 | 3/20 | 1.00 |
| ▸ | CA5A | P35218 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 1.00 |
| ▸ | APP | P05067 | 2/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | DPP4 | P27487 | 2/20 | 1.00 |
| ▸ | MMP1 | P03956 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caffeic Acid SCHEMBL23359 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL30501140 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL29447135 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL30050844 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL29353048 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL3682144 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL7064846 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL23358 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL21114743 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL9477189 | 0.98 | KDM4E (0.96) | KDM4EHSD17B10CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110241146-A | A kind of 3,4- dihydroxycinnamic acid that combination enzyme process prepares the method for 3,4- dihydroxycinnamic acid and produced by this method | 杭州唯铂莱生物科技有限公司 | 2019-09-17 | — | — | CN | claimed |
| WO-2015194710-A1 | COMPOSITION COMPRISING MESENCHYMAL STEM CELLS TREATED WITH STAT3 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING IMMUNE DISEASES | 가톨릭대학교 산학협력단 | 2015-12-23 | — | — | WO | claimed |
| US-11976063-B2 | Pharmaceutical composition comprising berberine and ursodeoxycholic acid for the treatment of various diseases or disorders | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2024-05-07 | — | — | US | disclosed |
| US-20230348457-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230295151-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11685735-B2 | Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| CN-114805385-A | Method for preparing lactalbumin-caffeic acid conjugate based on molecular probe technology | 南京农业大学 | 2022-07-29 | — | — | CN | disclosed |
| US-20210300915-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| WO-2021141452-A1 | COMPOSITION FOR INDUCING DIFFERENTIATION INTO INSULIN-PRODUCING CELLS, AND USE THEREOF | 서울대학교 산학협력단 | 2021-07-15 | — | — | WO | disclosed |
| US-10988471-B2 | Pharmaceutical composition comprising berberine ursodeoxycholic acid salt for the treatment of various diseases or disorders | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| EP-3174874-B1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) | 2020-09-02 | — | — | EP | disclosed |
| CN-103649713-B | Image analysis method and system for samples processed by programmable quantitative assays | 丹麦达科有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-20170037043-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| WO-2015194710-A1 | COMPOSITION COMPRISING MESENCHYMAL STEM CELLS TREATED WITH STAT3 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING IMMUNE DISEASES | 가톨릭대학교 산학협력단 | 2015-12-23 | — | — | WO | disclosed |
| US-20130005508-A1 | GOLF BALL | DUNLOP SPORTS CO. LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| EP-2370086-A2 | METHODS AND COMPOSITIONS FOR ALTERING HEALTH, WELLBEING, AND LIFESPAN | Lifespan Extension Llc (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011079212-A2 | METHODS AND COMPOSITIONS FOR IDENTIFYING, PRODUCING AND USING PLANT-DERIVED PRODUCTS MODULATING CELL FUNCTION AND AGING | LifeSpan Extension, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110159121-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING, PRODUCING AND USING PLANT-DERIVED PRODUCTS FOR MODULATING CELL FUNCTION AND AGING | LifeSpan Extension, LLC | 2011-06-30 | — | — | US | disclosed |
| US-7879582-B2 | Design of unpaired forward and reverse primers having homology to 5' end of one template and to the 3' end of another template; genetic engineering | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| EP-1113790-B1 | USE OF A CINNAMIC ACID DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OR TREATING ELEVATED BLOOD LIPID LEVEL-RELATED DISEASES | KOREA RES INST OF BIOSCIENCE (KR) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037043-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | CYP27A1, NR1H4, CYP7A1 | KDM4E 3717/4885HSD17B10 330/4885CA12 4229/4885 |
| US-20230348457-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | CYP27A1, NR1H4, CYP7A1 | KDM4E 3717/4885HSD17B10 330/4885CA12 4229/4885 |
| US-10988471-B2 | Pharmaceutical composition comprising berberine ursodeoxycholic acid salt for the treatment of various diseases or disorders | CYP27A1, SLC10A1, NR1H4 | KDM4E 3528/4885HSD17B10 265/4885CA12 3939/4885 |
| US-20210300915-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | CYP27A1, NR1H4, CYP7A1 | KDM4E 3717/4885HSD17B10 330/4885CA12 4229/4885 |
| US-11685735-B2 | Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders | CPT1B, CYP27A1, GLS2 | KDM4E 3119/4885HSD17B10 312/4885CA12 4315/4885 |
| US-20230295151-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | CYP27A1, NR1H4, CYP7A1 | KDM4E 3717/4885HSD17B10 330/4885CA12 4229/4885 |
| US-11976063-B2 | Pharmaceutical composition comprising berberine and ursodeoxycholic acid for the treatment of various diseases or disorders | CYP27A1, NR1H4, CPT1B | KDM4E 3553/4885HSD17B10 260/4885CA12 4389/4885 |
| US-20110159121-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING, PRODUCING AND USING PLANT-DERIVED PRODUCTS FOR MODULATING CELL FUNCTION AND AGING | TFAM, POLRMT, CS | KDM4E 2318/4885HSD17B10 1092/4885CA12 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.